Antibody-based therapy discovered at The Lundquist Institute is several steps closer to treating a lethal fungal infection
The Lundquist Institute holds both U.S. and international patents for this humanized antibody and has granted Vitalex, a Lundquist spin-off company, the commercial rights to advance this therapeutic ...
European Medical Journal13d
Novel Oral Norovirus Vaccine Shows Strong Immune Response
A new orally administered norovirus vaccine tablet has demonstrated promising safety and immunogenicity in older adults.
Medscape3d
Bivalent RSV Vaccine Shows Sustained Efficacy and Safety Through Two Seasons in Older Adults
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...
Medscape7d
Chikungunya Vaccine Shows Strong Immune Response in Prior Recipients of Alphavirus Vaccine
The chikungunya virus virus-like particle vaccine is well tolerated and shows high immunogenicity in both previous recipients ...
CURE3d
Global Submission Seeks Approval for Sugemalimab Treatment in NSCLC
An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...
Pharmabiz2d
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer: Suzhou, China Tuesday, March 25, 2025, 17:00 Hrs [IST] C ...
health.economictimes.indiatimes4d
Antibody-based therapy several notches closer to treat lethal mucormycosis: Study
Although both protect from infection, the humanized antibody reduces immunogenicity and enhances therapeutic effect when used in humans, a major translational step. Early tests show that VX-01 is ...